{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:04:14Z","timestamp":1784826254627,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jgar.2025.06.015","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:50:17Z","timestamp":1750852217000},"page":"217-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Real-world analysis of ceftolozane\/tazobactam prescribing patterns and effectiveness: SPECTRA analysis on chronic pulmonary diseases and respiratory-related infections"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-9526","authenticated-orcid":false,"given":"Emre","family":"Yucel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6523-8229","authenticated-orcid":false,"given":"Florian","family":"Thalhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brune","family":"Akrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huina","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6560-054X","authenticated-orcid":false,"given":"Sunny","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10325","key":"10.1016\/j.jgar.2025.06.015_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jgar.2025.06.015_bib0002","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrmicro.2017.122","article-title":"New opportunities for managing acute and chronic lung infections","volume":"16","author":"Cookson","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"10.1016\/j.jgar.2025.06.015_bib0003","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/CCM.0000000000005298","article-title":"Descriptive epidemiology and outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2012\u20132019","volume":"50","author":"Zilberberg","year":"2022","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2025.06.015_bib0004","unstructured":"Healthcare-Associated Infections (HAIs): Gram-negative bacteria infections in healthcare settings. https:\/\/www.cdc.gov\/hai\/organisms\/gram-negative-bacteria.html, accessed 27.9.2023."},{"key":"10.1016\/j.jgar.2025.06.015_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-physiol-021119-034610","article-title":"Aging and lung disease","volume":"82","author":"Cho","year":"2020","journal-title":"Annu Rev Physiol"},{"issue":"7","key":"10.1016\/j.jgar.2025.06.015_bib0006","article-title":"Novel antibiotics for gram-negative nosocomial pneumonia","volume":"13","author":"Almyroudi","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.06.015_bib0007","unstructured":"Ceftolozane\/tazobactam (ZERBAXA\u00ae) Prescribing information. 2022. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206829s011s012lbl.pdf, accessed 9.7.2025."},{"issue":"12","key":"10.1016\/j.jgar.2025.06.015_bib0008","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jgar.2025.06.015_bib0009","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"9981","key":"10.1016\/j.jgar.2025.06.015_bib0010","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jgar.2025.06.015_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2025.06.015_bib0012","doi-asserted-by":"crossref","first-page":"35","DOI":"10.37201\/req\/s01.10.2021","article-title":"Ceftolozane-tazobactam: when, how and why using it?","volume":"34","author":"Lopez Montesinos","year":"2021","journal-title":"Rev Esp Quimioter"},{"issue":"1","key":"10.1016\/j.jgar.2025.06.015_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00115-20","article-title":"New beta-lactam-beta-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.jgar.2025.06.015_bib0014","doi-asserted-by":"crossref","first-page":"dlac131","DOI":"10.1093\/jacamr\/dlac131","article-title":"Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane\/tazobactam in acute care inpatient facilities, Houston, Texas, USA","volume":"5","author":"Tran","year":"2023","journal-title":"JAC Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.jgar.2025.06.015_bib0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13756-021-00933-8","article-title":"Real-world use of ceftolozane\/tazobactam: a systematic literature review","volume":"10","author":"Puzniak","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2025.06.015_bib0016","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jgar.2022.01.023","article-title":"Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study","volume":"28","author":"Almangour","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.06.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgar.2025.01.007","article-title":"Unveiling results and insights from multinational, multicenter study of prescribing patterns and effectiveness of ceftolozane\/tazobactam real-world analysis (SPECTRA)","author":"Soriano","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"issue":"10","key":"10.1016\/j.jgar.2025.06.015_bib0018","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/antibiotics9100640","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam for multidrug-resistant gram-negative infections in immunocompetent patients: a single-center retrospective study","volume":"9","author":"Cultrera","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2025.06.015_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.015_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1405376","article-title":"Pseudomonas aeruginosa in chronic lung disease: untangling the dysregulated host immune response","volume":"15","author":"Nickerson","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jgar.2025.06.015_bib0021","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw172.1603","article-title":"Ceftolozane\/tazobactam: outpatient treatment of gram-negative infections at physician office infusion centers (POICs)","author":"Nathan","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.015_bib0022","first-page":"1625","article-title":"Real-world outpatient utilization of ceftolozane\/tazobactam in physician office infusion centers (OICs)","author":"Van Anglen","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.jgar.2025.06.015_bib0023","doi-asserted-by":"crossref","first-page":"ofaa014","DOI":"10.1093\/ofid\/ofaa014","article-title":"Clinical and safety evaluation of continuously infused ceftolozane\/Tazobactam in the outpatient setting","volume":"7","author":"Jones","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.jgar.2025.06.015_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01350-17","article-title":"In vitro comparison of ceftolozane-tazobactam to traditional beta-lactams and ceftolozane-tazobactam as an alternative to combination antimicrobial therapy for Pseudomonas aeruginosa","volume":"61","author":"Goodlet","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:15:52Z","timestamp":1777101352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"alternative-id":["S2213716525001468"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.06.015","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world analysis of ceftolozane\/tazobactam prescribing patterns and effectiveness: SPECTRA analysis on chronic pulmonary diseases and respiratory-related infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}